Myovant board balks as majority owner Sumitomo swoops in with a $2.5B deal to buy them out

John Carroll

Editor & Founder

Three years after Sumitomo scooped up Roivant’s 46% stake in the publicly traded Myovant $MYOV as part of a 5-company, $3 billion deal, they’re coming …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Myovant board balks as majority owner Sumitomo swoops in with a $2.5B deal to buy them out

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Post-Hoc: Pharma CEOs' alternative reality with Trump

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

FDA lifts hold on Entrada's Duchenne drug after two years

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

How AI can address ongoing challenges in the life sciences industry

My­ovant board balks as ma­jor­i­ty own­er Sum­it­o­mo swoops in with a $2.5B deal to buy them out

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Myovant board balks as majority owner Sumitomo swoops in with a $2.5B deal to buy them out